Analytics, not advice. Rankings and scores describe past performance and are not recommendations.
32slipping
Latest NAV
₹171.5474
as of 07 Aug 2026
AUM
—
Expense ratio
—
Inception
14 May 2026
FundScore
32/100slipping
Rank #207 of 322 · top 68%
A daily percentile of this fund’s past performance within its SEBI category — analytics, not advice, and not a prediction or recommendation.
Trailing returns
Annualised returns to the latest NAV. Refreshed nightly.
1M
3.61%
3M
8.64%
6M
18.50%
1Y
17.23%
3Y CAGR
20.08%
5Y CAGR
13.75%
Since incep.
14.73%
NAV history
Zoom and pan · ranges from 1M to since-inception.
Rolling returns
Every 30-day step. The true distribution, not cherry-picked.
Rank history
Percentile within category over the last 2 years.
FundScore components
Pro-only breakdown of consistency, recency, and volatility scores.
Upgrade to Pro to see the raw drivers behind this scheme's FundScore label.
Pro
Market-cap distribution
Large / mid / small / micro-cap split of this fund's equity holdings, from its latest look-through portfolio. Shown as a share of classified equity.
Large cap64.0%
Mid cap34.3%
Small cap1.7%
Stock holdings
Latest portfolio disclosure for this scheme. Snapshot as of 30 Jun 2026.
Sun Pharmaceutical Industries Ltd.
equity
18.13%
Apollo Hospitals Enterprise Ltd.
equity
8.21%
MAX Healthcare Institute Ltd
equity
7.72%
Divi's Laboratories Ltd.
equity
7.68%
Dr. Reddy's Laboratories Ltd.
equity
7.60%
Cipla Ltd.
equity
7.58%
Laurus Labs Ltd.
equity
5.43%
Lupin Ltd.
equity
5.40%
Fortis Healthcare Ltd.
equity
4.58%
Torrent Pharmaceuticals Ltd.
equity
4.46%
Aurobindo Pharma Ltd.
equity
4.02%
Glenmark Pharmaceuticals Ltd.
equity
3.05%
Alkem Laboratories Ltd.
equity
3.00%
Biocon Ltd.
equity
2.74%
Mankind Pharma Ltd.
equity
2.65%
Zydus Lifesciences Ltd.
equity
2.56%
IPCA Laboratories Ltd.
equity
2.17%
Abbott India Ltd.
equity
1.22%
Piramal Pharma Ltd.
equity
0.96%
Syngene International Ltd.
equity
0.77%